Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine CandidateBusiness Wire • 05/18/21
GlaxoSmithKline and Sanofi plan to join vaccine race with booster dosesProactive Investors • 05/17/21
Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This YearForbes • 05/17/21
GlaxoSmithKline, Sanofi post positive mid-stage trial results for COVID-19 vaccineProactive Investors • 05/17/21
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trialGlobeNewsWire • 05/17/21
Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shotBusiness Insider • 05/17/21
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From HillhouseSeeking Alpha • 05/16/21
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal StudyBenzinga • 05/13/21
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19GlobeNewsWire • 05/07/21
GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/28/21
GlaxoSmithKline emerges as unlikely loser of COVID-19 pandemic – but will a return to normality be enough to sort out trouble?Proactive Investors • 04/28/21
GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 OutlookBenzinga • 04/28/21